Medicare AdvantageCoverageMedium impact
Gene Expression Profiling for Cancer Indications - Medicare Advantage (Revised)
Humana·Oncology, Hematology, Pathology +3 more·Medicare Advantage
Effective date
May 1, 2026
We identified it
Jun 24, 2026
Summary
Humana Medicare Advantage has updated their gene expression profiling policy for cancer indications, effective May 1, 2026. This policy covers various molecular diagnostic tests and biomarkers for multiple cancer types including breast, prostate, lung, colon, melanoma, and bladder cancers.
Action Required
By May 1, 2026: Review and update prior authorization procedures for gene expression profiling tests used in cancer diagnosis and treatment planning. Billing team should verify coverage requirements for molecular diagnostic tests against the updated policy guidelines. Ensure documentation requirements align with new policy standards for all cancer-related genetic testing services.